Hair Growth in a Patient with Alopecia Areata on Tocilizumab
Author(s) -
Chloe J. Walker,
Kelly E. Flanagan,
James T. Pathoulas,
Isabel Pupo Wiss,
Maryanne M. Senna
Publication year - 2021
Publication title -
skin appendage disorders
Language(s) - English
Resource type - Journals
eISSN - 2296-9195
pISSN - 2296-9160
DOI - 10.1159/000516300
Subject(s) - alopecia areata , tocilizumab , medicine , hair growth , concomitant , monoclonal , dermatology , monoclonal antibody , immunology , antibody , disease , physiology
Tocilizumab (TCZ), a recombinant humanized antihuman monoclonal antibody targeting interleukin-6 (IL-6) signaling, is often utilized in the management of autoimmune disease. Few reports have demonstrated hair growth changes in patients on TCZ. Case Presentation: Herein, we review the literature and report a 21-year-old woman with progressive alopecia areata (AA) presenting with AA improvement while on TCZ for concomitant posterior uveitis. Discussion: Our case demonstrates the potential ability of TCZ to disrupt IL-6 signaling involved in AA, leading to hair loss and regrowth.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom